The pharmacokinetics of fluvoxamine after single oral administration of 25, 50, and 100mg fluvoxamine maleate was studied in a three-way cross-over study in 12 healthy male subjects. Fluvoxamine was administered orally in a solution. For doseproportionality, AUC, and C,-dose relationships were evalu
Plasma concentrations and pharmacokinetics of dihydralazine after single oral doses to human subjects
β Scribed by A. R. Waller; L. F. Chasseaud; T. Taylor; A. Darragh; D. A. O'Kelly
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- English
- Weight
- 295 KB
- Volume
- 1
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
After single oral doses of 20 mg of a suspension of dihydralazine sulphate to human subjects, the peak of mean plasma concentrations of dihydralazine of 47Β·0 ng ml^β1^ Β± 11Β·0 standard deviation (S.D.) (n = 7) was reached at 1 h. Mean concentrations declined biphasically with apparent halfβlives of 0Β·57 and 4Β·96 h respectively.
Dihydralazine was partly converted to hydralazine. The peak of mean plasma concentrations of the latter drug of 3Β·9 ng ml^β1^ Β± 1Β·7 S.D. (n = 7) occurred at 1β2 h after dosing with dihydralazine sulphate and declined to 1β5 ng ml^β1^ Β± 1Β·5 S.D. at 6 h.
Of the seven subjects studied, three were classified as fast and four as slow acetylators. Mean clearances appeared to be slightly more rapid in fast acetylators (1Β·63 1 min^β1^ Β± 0Β·32 S.D.) when compared to slow acetylators (1Β·31 1 min^β1^ Β± 0Β·31 S.D.) but this difference and differences in plasma concentrations and in areas under the plasma drug concentrationβtime curves were not significant (p > 0Β·1).
π SIMILAR VOLUMES
Furosemide solution was orally administered to 21 healthy adult males to determine dose proportionality over the dose range used and the reproducibility of disposition following a repeated dose. Furosemide solution was given in doses of 20,40, and 80mg, with the 40 mg dose repeated once. Blood was c
The pharmacokinetics of a new serotonin 5-HT 2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg -1 and intravenous doses of 1, 3 and 6 mg kg -1 were administered in beagle dogs. Moreover, the steady state pharmacokinetics of 1, 3 and 6 mg kg -1 doses were studied. Der
## Abstract Dolasetron is a 5βhydroxytryptamine antagonist active at type III receptors; it is presently undergoing clinical evaluation for the reduction/prevention of cancer chemotherapyinduced nausea and vomiting. A previous study demonstrated that following intravenous administration to healthy
## Abstract A comparative bioavailability study was conducted with two capsule formulations of danazol (200 mg) in 16 healthy adult male volunteers. Fasting subjects received single doses (400 mg) of each formulation on separate occasions 1 week apart. Blood samples were drawn at specified times up
Procaterol is a potent, orally active &-agonist bronchodilator useful in the treatment of reversible bronchospastic disease. It is effective when administered as single or multiple (Q8H) 50 and 75pg doses. As part of the clinical development of procaterol, the pharmacokinetics and dose proportionali